Literature DB >> 26498282

Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia.

Yan Fei Qi, Juan Zhang, Lei Wang, Vinayak Shenoy, Eric Krause, S Paul Oh, Carl J Pepine, Michael J Katovich, Mohan K Raizada.   

Abstract

High-mobility group box 1 (HMGB1) triggers and amplifies inflammation cascade following ischemic injury, and its elevated levels are associated with adverse clinical outcomes in patients with myocardial infarction (MI). Angiotensin-converting enzyme 2 (ACE2), a key member of vasoprotective axis of the renin-angiotensin system (RAS), regulates cardiovascular functions and exerts beneficial effects in cardiovascular disease. However, the association between HMGB1 and ACE2 has not been studied. We hypothesized that overexpression of ACE2 provides cardioprotective effects against MI via inhibiting HMGB1 and inflammation. ACE2 knock-in (KI) mice and littermate wild-type (WT) controls were subjected to either sham or coronary artery ligation surgery to induce MI. Heart function was assessed 4 weeks after surgery using echocardiography and Millar catheterization. Tissues were collected for histology and analysis of the expression of HMGB1, RAS components, and inflammatory cytokines. ACE2 in the heart of the ACE2 KI mice was 58-fold higher than WT controls. ACE2-MI mice exhibited a remarkable preservation of cardiac function and reduction of infarct size in comparison to WT-MI mice. Notably, ACE2 overexpression significantly reduced the MI-induced increase in apoptosis, macrophage infiltration, and HMGB1 and proinflammatory cytokine expression (TNF-α and IL-6). Moreover, in an in vitro study, ACE2 activation prevented the hypoxia-induced cell death and upregulation of HMGB1 in adult cardiomyocytes. This protective effect is correlated with downregulation of HMGB1 and downstream proinflammatory cascades, which could be useful for the development of novel treatment for ischemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26498282      PMCID: PMC4842346          DOI: 10.1007/s00109-015-1356-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  46 in total

1.  The angiotensin II AT2 receptor is an AT1 receptor antagonist.

Authors:  S AbdAlla; H Lother; A M Abdel-tawab; U Quitterer
Journal:  J Biol Chem       Date:  2001-08-15       Impact factor: 5.157

2.  ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension.

Authors:  Srinivas Sriramula; Jeffrey P Cardinale; Eric Lazartigues; Joseph Francis
Journal:  Cardiovasc Res       Date:  2011-09-27       Impact factor: 10.787

3.  Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology.

Authors:  Yanfei Qi; Juan Zhang; Colleen T Cole-Jeffrey; Vinayak Shenoy; Andrew Espejo; Mina Hanna; Chunjuan Song; Carl J Pepine; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

4.  Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension.

Authors:  Tsukasa Nakamura; Eiichi Sato; Nobuharu Fujiwara; Yasuhiro Kawagoe; Shingo Yamada; Yoshihiko Ueda; Hikaru Koide
Journal:  Am J Med Sci       Date:  2012-01       Impact factor: 2.378

5.  Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.

Authors:  Koichi Yamamoto; Mitsuru Ohishi; Tomohiro Katsuya; Norihisa Ito; Masashi Ikushima; Masaharu Kaibe; Yuji Tatara; Atsushi Shiota; Sumio Sugano; Satoshi Takeda; Hiromi Rakugi; Toshio Ogihara
Journal:  Hypertension       Date:  2006-02-27       Impact factor: 10.190

6.  Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats.

Authors:  Annemarieke E Loot; Anton J M Roks; Robert H Henning; René A Tio; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

7.  Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction.

Authors:  Plinio Cirillo; Francesco Giallauria; Mario Pacileo; Gianluca Petrillo; Mariantonietta D'Agostino; Carlo Vigorito; Massimo Chiariello
Journal:  J Card Fail       Date:  2009-01-09       Impact factor: 5.712

8.  Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure.

Authors:  F Pieruzzi; Z A Abassi; H R Keiser
Journal:  Circulation       Date:  1995-11-15       Impact factor: 29.690

9.  Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology.

Authors:  Shant Der Sarkissian; Justin L Grobe; Lihui Yuan; Dhruv R Narielwala; Glenn A Walter; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2008-02-04       Impact factor: 10.190

Review 10.  Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.

Authors:  Kiyoshi Kikuchi; Salunya Tancharoen; Takashi Ito; Yoko Morimoto-Yamashita; Naoki Miura; Ko-ichi Kawahara; Ikuro Maruyama; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

View more
  25 in total

1.  Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice.

Authors:  Lei A Wang; Annette D de Kloet; Michael D Smeltzer; Karlena M Cahill; Helmut Hiller; Erin B Bruce; David J Pioquinto; Jacob A Ludin; Michael J Katovich; Mohan K Raizada; Eric G Krause
Journal:  Neuropharmacology       Date:  2018-05-01       Impact factor: 5.250

2.  High-dose intramyocardial HMGB1 induces long-term cardioprotection in sheep with myocardial infarction.

Authors:  María Del Rosario Bauzá; Carlos Sebastián Giménez; Paola Locatelli; Andrea De Lorenzi; Anna Hnatiuk; Maurizio C Capogrossi; Alberto Crottogini; Luis Cuniberti; Fernanda Daniela Olea
Journal:  Drug Deliv Transl Res       Date:  2019-10       Impact factor: 4.617

3.  Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes.

Authors:  Santosh Kumar Goru; Almesh Kadakol; Vajir Malek; Anuradha Pandey; Nisha Sharma; Anil Bhanudas Gaikwad
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

4.  An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats.

Authors:  Domenico G Della Rocca; Bradley J Willenberg; Yanfei Qi; Chelsey S Simmons; Andres Rubiano; Leonardo F Ferreira; Tianyao Huo; John W Petersen; Prashant J Ruchaya; Prateek S Wate; Elizabeth A Wise; Eileen M Handberg; Christopher R Cogle; Christopher D Batich; Barry J Byrne; Carl J Pepine
Journal:  Int J Cardiol       Date:  2016-06-25       Impact factor: 4.164

5.  Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors.

Authors:  Lei Wang; Annette D de Kloet; Dipanwita Pati; Helmut Hiller; Justin A Smith; David J Pioquinto; Jacob A Ludin; S Paul Oh; Michael J Katovich; Charles J Frazier; Mohan K Raizada; Eric G Krause
Journal:  Neuropharmacology       Date:  2016-01-06       Impact factor: 5.250

6.  Gut Pathology and Its Rescue by ACE2 (Angiotensin-Converting Enzyme 2) in Hypoxia-Induced Pulmonary Hypertension.

Authors:  Ravindra K Sharma; Aline C Oliveira; Tao Yang; Marianthi M Karas; Jing Li; Gilberto O Lobaton; Victor P Aquino; Iñaki Robles-Vera; Annette D de Kloet; Eric G Krause; Andrew J Bryant; Amrisha Verma; Qiuhong Li; Elaine M Richards; Mohan K Raizada
Journal:  Hypertension       Date:  2020-05-18       Impact factor: 10.190

7.  Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study).

Authors:  Aliza Hussain; Olive Tang; Caroline Sun; Xiaoming Jia; Elizabeth Selvin; Vijay Nambi; Aaron Folsom; Gerardo Heiss; Faiez Zannad; Thomas Mosley; Salim S Virani; Josef Coresh; Eric Boerwinkle; Bing Yu; Jonathan W Cunningham; Amil M Shah; Scott D Solomon; James A de Lemos; Ron C Hoogeveen; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2021-02-02       Impact factor: 2.778

Review 8.  Advances in use of mouse models to study the renin-angiotensin system.

Authors:  Jacqueline M Emathinger; Jonathan W Nelson; Susan B Gurley
Journal:  Mol Cell Endocrinol       Date:  2021-03-28       Impact factor: 4.369

9.  Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats.

Authors:  Hui Ma; Jing Kong; Yu-Lin Wang; Jun-Long Li; Nai-Hao Hei; Xin-Ran Cao; Jing-Jing Yang; Wen-Jiang Yan; Wen-Jing Liang; Hong-Yan Dai; Bo Dong
Journal:  Oncotarget       Date:  2017-04-11

10.  COVID-19 and Diabetes: The Importance of Controlling RAGE.

Authors:  Ernestina M De Francesco; Veronica Vella; Antonino Belfiore
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.